All In Biotech

Drug Trial Radar · NCT06284876

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

416

Planned (sponsor's estimate)

Start

Jul 23, 2024

Primary completion

Aug 30, 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24

Conditions

  • Peptic Ulcer

Interventions

  • IlaprazoleDrug

    Ilaprazole 10 mg

  • LansoprazoleDrug

    Lansoprazole 15 mg

  • Ilaprazole PlaceboDrug

    Placebo of Ilaprazole 10 mg

  • Lansoprazole PlaceboDrug

    Placebo of Lansoprazole 15 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ilaprazole, Lansoprazole peptic ulcerTime frame: at 24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chung Ang University Hospital

    Seoul, South Korea

  • Chung-Ang University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.